
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …

French pharma group Ipsen has snapped up privately-owned UK life sciences firm Syntaxin for an upfront payment of €28 million …
A new photodynamic therapy treatment for human papilloma virus (HPV) associated diseases of the cervix has shown potential in a …

Ipsen has appointed Claude Bertrand (pictured) chief scientific officer and Jacques-Pierre Moreau chief scientific advisor.Bertrand moves to the company next …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

